ArticleMolecular syndromology2026
Clinical and Molecular Features of 11 Patients with Different Subtypes of Ehlers-Danlos Syndrome.
Article in Molecular syndromology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ehlers-Danlos syndrome (EDS) comprises a group of clinically and genetically heterogeneous connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and increased tissue fragility. As collagen is present in every organ system, EDS affects multiple body systems, and although its subtypes share overlapping features, each also exhibits distinctive clinical characteristics. Methods: We report 11 EDS patients from eight unrelated families. Whole-exome sequencing, clinical exome sequencing, and Sanger sequencing were performed for genetic diagnosis. Results: Six EDS subtypes were identified: cardiac valvular EDS, dermatosparaxis EDS, musculocontractural EDS type 1, combined osteogenesis imperfecta/EDS type 2, brittle cornea syndrome type 2, and kyphoscoliotic EDS types 1 and 2. All patients exhibited joint hypermobility and skin hyperextensibility. Eight different variants were detected, including two novel variants; five were classified as pathogenic, two as likely pathogenic, and one as a variant of uncertain significance. Molecular diagnoses influenced clinical management by enabling subtype-specific surveillance, such as cardiologic monitoring in cardiac valvular EDS, early ophthalmologic intervention in brittle cornea syndrome, avoidance of invasive procedures in dermatosparaxis EDS, implementation of fracture-preventive measures in patients with combined osteogenesis imperfecta/EDS, and improved surgical risk management across all EDS subtypes. Conclusion: This study expands the clinical and molecular spectrum of EDS by identifying two novel pathogenic variants and revealing previously unreported clinical findings. The results emphasize intrafamilial variability and the need to consider possible dual diagnoses, particularly in consanguineous families. Detailed phenotyping combined with comprehensive molecular testing improves subtype delineation and guides patient-specific surveillance and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.